Stephan W. Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephan W. Morris has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Zhigui Ma
Department of Pathology
4 shared publicationsA Slupianek
2 shared publicationsG Hoser
2 shared publicationsJohann K. Hitzler
Department of Paediatrics, Division of Haematology/Oncology, Program in Developmental Biology, The Hospital for Sick Children
2 shared publicationsL Xue
2 shared publicationsLiquan Xue
Departments of Pathology and Oncology, St Jude Children’s Research Hospital, 332 North Lauderdale Street, Mail Stop 343, Memphis, TN 38105, USA
2 shared publications
Latest Publications
- 17 July 2009
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (16) , 4981-5004
Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach
- 17 July 2009
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (16) , 4981-5004
Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach
- 1 March 2009
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 9 (3) , 331-356
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms – the most common being...
- 1 March 2009
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 9 (3) , 331-356
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms – the most common being...
- 10 August 2007
- Published by Wiley in Medicinal Research Reviews
- Vol. 28 (3) , 372-412
Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) involved in the genesis of several human cancers; indeed, ALK was initially identified in constitutively activated and oncogenic fusion forms—the most common being nucleophosmin (NPM)‐ALK—in a non‐Hodgkin's lymphoma (NHL) known as anaplastic large‐cell lymphoma (ALCL) and subsequent studies identified ALK fusions in the human sarcomas called inflammatory myofibroblastic tumors (IMTs). In addition, two recent reports have suggested that the ALK fusion, TPM4‐ALK, may be involved in the genesis of a subset of esophageal squamous cell carcinomas. While the cause‐effect relationship between ALK fusions and malignancies such as ALCL and IMT is very well established, more circumstantial links implicate the involvement of the full‐length, normal ALK receptor in the genesis of additional malignancies including glioblastoma, neuroblastoma, breast cancer, and others; in these instances, ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops involving the reported ALK ligands, pleiotrophin (PTN) and midkine (MK). There are no currently available ALK small‐molecule inhibitors approved for clinical cancer therapy; however, recognition of the variety of malignancies in which ALK may play a causative role has recently begun to prompt developmental efforts in this area. This review provides a succinct summary of normal ALK biology, the confirmed and putative roles of ALK fusions and the full‐length ALK receptor in the development of human cancers, and efforts to target ALK using small‐molecule kinase inhibitors. © 2007 Wiley Periodicals, Inc. Med Res Rev, 28, No. 3, 372–412, 2008
- 10 August 2007
- Published by Wiley in Medicinal Research Reviews
- Vol. 28 (3) , 372-412
Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) involved in the genesis of several human cancers; indeed, ALK was initially identified in constitutively activated and oncogenic fusion forms—the most common being nucleophosmin (NPM)‐ALK—in a non‐Hodgkin's lymphoma (NHL) known as anaplastic large‐cell lymphoma (ALCL) and subsequent studies identified ALK fusions in the human sarcomas called inflammatory myofibroblastic tumors (IMTs). In addition, two recent reports have suggested that the ALK fusion, TPM4‐ALK, may be involved in the genesis of a subset of esophageal squamous cell carcinomas. While the cause‐effect relationship between ALK fusions and malignancies such as ALCL and IMT is very well established, more circumstantial links implicate the involvement of the full‐length, normal ALK receptor in the genesis of additional malignancies including glioblastoma, neuroblastoma, breast cancer, and others; in these instances, ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops involving the reported ALK ligands, pleiotrophin (PTN) and midkine (MK). There are no currently available ALK small‐molecule inhibitors approved for clinical cancer therapy; however, recognition of the variety of malignancies in which ALK may play a causative role has recently begun to prompt developmental efforts in this area. This review provides a succinct summary of normal ALK biology, the confirmed and putative roles of ALK fusions and the full‐length ALK receptor in the development of human cancers, and efforts to target ALK using small‐molecule kinase inhibitors. © 2007 Wiley Periodicals, Inc. Med Res Rev, 28, No. 3, 372–412, 2008
- 1 August 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (15) , 5809-5826
Acute Myeloid Leukemia-Associated Mkl1 (Mrtf-a) Is a Key Regulator of Mammary Gland Function
Transcription of immediate-early genes—as well as multiple genes affecting muscle function, cytoskeletal integrity, apoptosis control, and wound healing/angiogenesis—is regulated by serum response factor (Srf). Extracellular signals regulate Srf in part via a pathway involving megakaryoblastic leukemia 1 (Mkl1, also known as myocardin-related transcription factor A [Mrtf-a]), which coactivates Srf-responsive genes downstream of Rho GTPases. Here we investigate Mkl1 function using gene targeting and show the protein to be essential for the physiologic preparation of the mammary gland during pregnancy and the maintenance of lactation. Lack of Mkl1 causes premature involution and impairs expression of Srf-dependent genes in the mammary myoepithelial cells, which control milk ejection following oxytocin-induced contraction. Despite the importance of Srf in multiple transcriptional pathways and widespread Mkl1 expression, the spectrum of abnormalities associated with Mkl1 absence appears surprisingly restricted.
- 1 August 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (15) , 5809-5826
Acute Myeloid Leukemia-Associated Mkl1 (Mrtf-a) Is a Key Regulator of Mammary Gland Function
Transcription of immediate-early genes—as well as multiple genes affecting muscle function, cytoskeletal integrity, apoptosis control, and wound healing/angiogenesis—is regulated by serum response factor (Srf). Extracellular signals regulate Srf in part via a pathway involving megakaryoblastic leukemia 1 (Mkl1, also known as myocardin-related transcription factor A [Mrtf-a]), which coactivates Srf-responsive genes downstream of Rho GTPases. Here we investigate Mkl1 function using gene targeting and show the protein to be essential for the physiologic preparation of the mammary gland during pregnancy and the maintenance of lactation. Lack of Mkl1 causes premature involution and impairs expression of Srf-dependent genes in the mammary myoepithelial cells, which control milk ejection following oxytocin-induced contraction. Despite the importance of Srf in multiple transcriptional pathways and widespread Mkl1 expression, the spectrum of abnormalities associated with Mkl1 absence appears surprisingly restricted.
- Open Access
- 26 May 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (8) , 1492-1494
RBM15 and MKL1 mutational screening in megakaryoblastic leukemia cell lines and clinical samples
- 26 May 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (8) , 1492-1494
Open AccessRBM15 and MKL1 mutational screening in megakaryoblastic leukemia cell lines and clinical samples
- 11 March 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 37 (1) , 98-105
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal proliferation of transformed myofibroblasts, with a prominent inflammatory cell component, that can mimic other spindle cell processes such as nodular fasciitis, desmoid tumor, and gastrointestinal stromal tumor. Genetic analyses have recently demonstrated rearrangements of anaplastic lymphoma kinase (ALK), located at 2p23, in a subset of IMTs. Molecular characterizations have identified ALK fusions involving tropomyosin‐3 and ‐4 (TPM‐3 and ‐4), the clathrin heavy chain (CLTC), and the cysteinyl‐tRNA synthetase (CARS) genes as fusion partners. Here we describe two IMTs with a novel ALK fusion that involves the Ran‐binding protein 2 (RANBP2) gene at 2q13, which normally encodes a large (358‐kDa) nucleopore protein localized at the cytoplasmic side of the nuclear pore complex. The N‐terminal 867 residues of RANBP2 are fused to the cytoplasmic segment of ALK in the 1,430–amino acid RANBP2‐ALK chimeric protein. Myofibroblasts that express RANBP2‐ALK exhibit nuclear membrane‐associated ALK staining that is unique compared to the subcellular localization observed with other ALK fusions in IMT, presumably attributable to heteroassociation of the fusion with normal RANBP2 at the nuclear pore. These findings expand the spectrum of ALK abnormalities observed in IMT and further confirm the clonal, neoplastic nature of these lesions.
- 11 March 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 37 (1) , 98-105
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal proliferation of transformed myofibroblasts, with a prominent inflammatory cell component, that can mimic other spindle cell processes such as nodular fasciitis, desmoid tumor, and gastrointestinal stromal tumor. Genetic analyses have recently demonstrated rearrangements of anaplastic lymphoma kinase (ALK), located at 2p23, in a subset of IMTs. Molecular characterizations have identified ALK fusions involving tropomyosin‐3 and ‐4 (TPM‐3 and ‐4), the clathrin heavy chain (CLTC), and the cysteinyl‐tRNA synthetase (CARS) genes as fusion partners. Here we describe two IMTs with a novel ALK fusion that involves the Ran‐binding protein 2 (RANBP2) gene at 2q13, which normally encodes a large (358‐kDa) nucleopore protein localized at the cytoplasmic side of the nuclear pore complex. The N‐terminal 867 residues of RANBP2 are fused to the cytoplasmic segment of ALK in the 1,430–amino acid RANBP2‐ALK chimeric protein. Myofibroblasts that express RANBP2‐ALK exhibit nuclear membrane‐associated ALK staining that is unique compared to the subcellular localization observed with other ALK fusions in IMT, presumably attributable to heteroassociation of the fusion with normal RANBP2 at the nuclear pore. These findings expand the spectrum of ALK abnormalities observed in IMT and further confirm the clonal, neoplastic nature of these lesions.
- 5 March 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (9) , 1418-1424
Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14)
Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7–10% of acute lymphoblastic leukemia (ALL) and 5–6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL–AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL – the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation.
- 5 March 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (9) , 1418-1424
Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14)
Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7–10% of acute lymphoblastic leukemia (ALL) and 5–6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL–AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL – the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation.
- 10 September 2001
- Published by Springer Nature in Oncogene
- Vol. 20 (40) , 5623-5637
Translocations involving anaplastic lymphoma kinase (ALK)
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
- 10 September 2001
- Published by Springer Nature in Oncogene
- Vol. 20 (40) , 5623-5637
Translocations involving anaplastic lymphoma kinase (ALK)
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
- 1 September 2001
- Vol. 61 (17) , 6517-23
Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
The NPM/ALK fusion gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protein that containsthe amino-terminal portion of the nucleolar phosphoprotein nucleophosmin(NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). NPM/ALK encodes a constitutively activated tyrosine kinase that belongs to the family of tyrosine kinases activated by chromosomal translocation. Our studies show that NPM/ALK, similar to other members of this family, activates signal transducer and activator of transcription 5 (STAT5) and that this activation is essential for lymphomagenesis. NPM/ALK-mediated activation of STAT5 was demonstrated by detection of: (a) constitutive tyrosine phosphorylation and enhanced DNA binding ability of STAT5 in NPM/ALK-transformed cells; and (b) NPM/ALK-dependent stimulation of STAT5-mediated transactivation of the beta-casein promoter. Retroviral infection of NPM/ALK+ cells with a dominant-negative STAT5B mutant (STAT5-DNM) inhibited the antiapoptotic activity of NPM/ALK in growth factor and serum-free medium. In addition, STAT5-DNM inhibited proliferation and diminished the clonogenic properties of NPM/ALK-positive cells. Finally, SCID mice injected with NPM/ALK+ cells infected with a virus carrying STAT5-DNM survived significantly longer than mice inoculated with NPM/ALK+ cells infected with the empty virus. Necropsy identified a widespread ALK+ lymphoma in lymph nodes and liver of the affected animals. Together, our data indicate that NPM/ALK-induced activation of STAT5 may play an important role in NPM/ALK-mediated lymphomagenesis.
- 1 September 2001
- Vol. 61 (17) , 6517-23
Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
The NPM/ALK fusion gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protein that containsthe amino-terminal portion of the nucleolar phosphoprotein nucleophosmin(NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). NPM/ALK encodes a constitutively activated tyrosine kinase that belongs to the family of tyrosine kinases activated by chromosomal translocation. Our studies show that NPM/ALK, similar to other members of this family, activates signal transducer and activator of transcription 5 (STAT5) and that this activation is essential for lymphomagenesis. NPM/ALK-mediated activation of STAT5 was demonstrated by detection of: (a) constitutive tyrosine phosphorylation and enhanced DNA binding ability of STAT5 in NPM/ALK-transformed cells; and (b) NPM/ALK-dependent stimulation of STAT5-mediated transactivation of the beta-casein promoter. Retroviral infection of NPM/ALK+ cells with a dominant-negative STAT5B mutant (STAT5-DNM) inhibited the antiapoptotic activity of NPM/ALK in growth factor and serum-free medium. In addition, STAT5-DNM inhibited proliferation and diminished the clonogenic properties of NPM/ALK-positive cells. Finally, SCID mice injected with NPM/ALK+ cells infected with a virus carrying STAT5-DNM survived significantly longer than mice inoculated with NPM/ALK+ cells infected with the empty virus. Necropsy identified a widespread ALK+ lymphoma in lymph nodes and liver of the affected animals. Together, our data indicate that NPM/ALK-induced activation of STAT5 may play an important role in NPM/ALK-mediated lymphomagenesis.
- Open Access
- 1 May 2001
- Published by Wiley in British Journal of Haematology
- Vol. 113 (2) , 275-295
Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non‐hodgkin's lymphoma
- 1 May 2001
- Published by Wiley in British Journal of Haematology
- Vol. 113 (2) , 275-295
Open AccessAlk+ CD30+ lymphomas: a distinct molecular genetic subtype of non‐hodgkin's lymphoma